Yuyu Pharma, Inc.

KRX:000220.KS

4445 (KRW) • At close September 6, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 137,209.589138,881.056115,655.48598,119.84690,877.64483,096.44562,852.07471,578.93269,743.37562,816.22361,994.11561,984.73458,798.71452,027.33447,900.30745,014.22573,840.11773,393.135
Cost of Revenue 90,704.47985,567.91370,320.152,850.89244,267.32942,459.50832,866.39138,208.09238,870.76831,717.1929,623.07926,630.24625,563.80321,237.47921,042.1518,076.8826,306.44526,153.156
Gross Profit 46,505.10953,313.14445,335.38545,268.95546,610.31540,636.93729,985.68333,370.8430,872.60631,099.03232,371.03635,354.48833,234.91230,789.85526,858.15726,937.34547,533.67247,239.979
Gross Profit Ratio 0.3390.3840.3920.4610.5130.4890.4770.4660.4430.4950.5220.570.5650.5920.5610.5980.6440.644
Reseach & Development Expenses 7,187.6368,620.3744,008.2814,122.659876.6721,424.4111,690.9112,246.0551,245.2661,131.686999.218845.127922.65487.5471,421.1831,023.0612,846.723,131.281
General & Administrative Expenses 4,191.6764,956.9093,904.3313,639.6494,469.3494,339.2373,290.1554,412.9126,384.2757,001.0096,463.6494,839.7315,103.1224,474.574,126.3694,566.4985,266.8985,064.961
Selling & Marketing Expenses 11,707.30515,036.60512,471.85310,492.79811,587.58510,750.3997,161.2958,042.16,670.5717,221.9128,278.19911,647.74111,921.84410,520.8419,527.73812,496.03312,403.49910,092.952
SG&A 39,847.19419,993.51416,376.18414,132.44716,056.93415,089.63610,451.4512,455.01213,054.84614,222.92114,741.84816,487.47217,024.96614,995.41113,654.10717,062.53117,670.39715,157.913
Other Expenses -219.2225,291.36923,750.75220,742.92121,601.982322.191-183.72255.4191,061.196-6,648.931645.90564.87240.281,011.686562.1471,928.251-7.169312.793
Operating Expenses 47,254.0553,905.25744,135.21738,998.02738,535.58835,309.22326,417.49329,635.91429,258.84329,728.10130,615.86731,635.19631,133.48129,496.2726,270.44232,671.1537,529.57734,169.582
Operating Income -748.941691.7472,653.5086,270.9278,074.7275,327.4133,568.1913,734.9241,613.7611,370.9311,755.1693,719.2931,819.3321,293.584587.715-5,733.80610,004.09713,070.397
Operating Income Ratio -0.0050.0050.0230.0640.0890.0640.0570.0520.0230.0220.0280.060.0310.0250.012-0.1270.1350.178
Total Other Income Expenses Net -4,199.515-4,502.124-3,036.663-2,559.592-1,474.459-679.1821,245.0872,801.934-3,552.285-9,043.513.02-133.073-471.202-1,565.742,050.245-2,493.4515,571.389-910.405
Income Before Tax -4,948.456-3,810.377-383.1553,711.3356,600.2684,648.2324,813.2786,536.859-281.501-7,672.5782,629.6393,586.2191,348.13860.042,637.96-5,454.63915,575.48612,159.992
Income Before Tax Ratio -0.036-0.027-0.0030.0380.0730.0560.0770.091-0.004-0.1220.0420.0580.0230.0170.055-0.1210.2110.166
Income Tax Expense 98.436615.016537.1341,298.731,036.925336.122524.751391.285122.195-309.227697.759600.247-560.057-257.232364.568232.7372,009.3723,601.561
Net Income -7,180.9-4,425.393-920.2892,412.6054,722.2974,020.2914,541.4215,885.697-252.675-7,467.3731,876.5222,978.7271,906.7691,117.2722,273.392-5,687.37513,566.1148,558.432
Net Income Ratio -0.052-0.032-0.0080.0250.0520.0480.0720.082-0.004-0.1190.030.0480.0320.0210.047-0.1260.1840.117
EPS -441.41-266.9-57.67194.34377.83281.5406493.5-25.45-746.43178301161106.5218-452.981,041652.5
EPS Diluted -441.41-266.9-57.67194.34376.31281.5400493.5-25.45-746.43176.5301161106.5218-452.981,041652.5
EBITDA 4,858.3915,719.1257,156.4619,319.0111,022.948,217.0635,896.1165,905.8574,812.955-5,003.5824,259.1255,677.9443,831.2114,671.5393,177.955352.58714,728.26118,452.204
EBITDA Ratio 0.0350.0410.0620.0950.1210.0990.0940.0830.069-0.080.0690.0920.0650.090.0660.0080.1990.251